摘要
目的比较培美曲塞联合奈达铂或顺铂同步调强放疗(IMRT)治疗晚期肺腺癌的临床疗效。方法选取南方医科大学附属南海医院和广州医科大学肿瘤医院2012年1月—2014年3月收治的肺腺癌患者58例,根据治疗方案分为奈达铂组28例和顺铂组30例。两组患者均行同步IMRT,奈达铂组患者给予培美曲塞+奈达铂化疗方案,顺铂组患者给予培美曲塞+顺铂化疗方案;同步放化疗2个周期,放疗结束后均行维持化疗4个周期。比较两组患者临床疗效、生存曲线、中位生存时间、1年生存率、2年生存率及治疗期间毒副作用发生情况。结果两组患者临床疗效比较,差异无统计学意义(P>0.05)。截至2016年5月,两组患者生存曲线比较,差异无统计学意义(P>0.05);两组患者中位生存时间、1年生存率、2年生存率比较,差异无统计学意义(P>0.05)。两组患者中性粒细胞减少、贫血、血小板计数减少、食管炎、肺炎发生率比较,差异无统计学意义(P>0.05);奈达铂组患者恶心呕吐发生率低于顺铂组(P<0.05)。结论培美曲塞联合奈达铂或顺铂同步IMRT治疗晚期肺腺癌的临床疗效相当,但培美曲塞联合奈达铂治疗晚期肺腺癌的安全性较高。
Objective To compare the clinical effect on advanced lung adenocarcinoma between pemetrexed combined with nedaplatin and pemetrexed combined with cisplatin based on concurrent IMRT. Methods From January 2012 to March 2014, a total of 58 patients with lung adenocareinoma were selected in Nanhai Hospital Affiliated to Southern Medical University and Cancer Center of Guangzhou Medical University, and they were divided into A group （ n = 28） and B group （ n = 30） according to therapeutic regimens. Based on concurrent IMRT, patients of A group received pemetrexed combined with nedaplatin, while patients of B group received pemetrexed combined with cisplatin; both groups continuously treated for 2 cycles of concurrent IMRT and maintenance chemotherapy for 4 cycles. Clinical effect, survival curve, median overall survival, 1 - year survival rate, 2 - year survival rate, incidence of toxic and side effects during the treatment were compared between the two groups. Results No statistically significant differences of clinical effect was found between the two groups （ P 〉 0. 05 ） . Till May 2016, no statistically significant differences of survival curve was found between the two groups, nor was median overall survival, 1 - year survival rate or 2 - year survival rate （ P 〉 0. 05 ） . No statistically significant differences of incidence of neutrophil decrease, anemia, blood platelet count decrease, oesophagitis or pneumonia was found between the two groups （P 〉 0. 05 ）, while incidence of nausea and vomiting of A group was statistically significantly lower than that of B group （ P 〈 0. 05 ）. Conclusion Based on concurrent IMRT, pemetrexed combined with nedaplatin has similar clinical effect in treating advanced lung adenocarcinoma with pemetrexed combined with cisplatin, but it has higher safety.
出处
《实用心脑肺血管病杂志》
2016年第11期64-67,共4页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
基金
广东省佛山市医学类科技攻关项目(2015AB000572)
关键词
癌
非小细胞肺
培美曲塞
奈达铂
顺铂
化放疗
Carcinoma, non - small - cell lung
Pemetrexed
Nedaplatin
Cisplatin
Chemoradiotherapy
